Alpine Immune Sciences price target raised to $41 from $29 at RBC Capital

RBC Capital raised the firm’s price target on Alpine Immune Sciences to $41 from $29 and keeps an Outperform rating on the shares. The company’s povetacicept profile has been further strengthened by recent positive data from competitors and amplified by key opinion leaders’ interest in BAFF/APRIL’s B cell-depletion mechanism as a direct attack on IgA nephropathy’s root cause, the analyst tells investors in a research note. RBC adds its price target increase is due to povetacicept’s strong competitive positioning, the potential for greater validation by upcoming updates in the first half of the year, and a comfortable runway into 2026.